Press Releases

Avilar Therapeutics to Present In Vivo Non-Human Primate Data on ASGPR-Targeting Chimeras (ATACs) at the Keystone Symposium on Targeted Protein Degradation

WALTHAM, Mass., November 1, 2022 – Avilar Therapeutics, a biopharmaceutical company focused on extracellular protein degradation, today announced it will present preclinical data demonstrating the degradation of extracellular proteins using its asialoglycoprotein receptor (ASGPR) targeting chimeras (ATAC) platform at the Keystone Symposium on Targeted Protein Degradation being held in Vancouver, British Columbia, November 6-8, 2022.

The presentation will include pharmacokinetic (PK) and pharmacodynamic (PD) data from single and repeat-dose studies in non-human primates with monovalent ATAC degraders dosed subcutaneously and intravenously that target immunoglobulin G (IgG), an abundant extracellular protein.

Details of the presentation are as follows:

Title: ASGPR-Targeting Chimeras (ATACs): In Vitro and In Vivo Demonstration of the Degradation of Extracellular Proteins
Poster Number: 1011
Presenting Author: Alison Davis, PhD, Director of Biology
Poster Session Date and Time: Monday November 7, 2022, 7:30-10:00pm PT

The poster will be available on the Avilar website on Monday, November 7.

About Avilar Therapeutics

Avilar Therapeutics is a biopharmaceutical company pioneering the discovery and development of extracellular protein degraders, a new frontier in targeted protein degradation. Avilar develops ATACs (ASGPR Targeting Chimeras), a new class of protein degraders that shuttle disease-causing proteins from circulation to the endolysosome where the unwanted proteins are degraded. Avilar has built a proprietary ATAC platform that includes novel, high-affinity, small molecule ASGPR ligands and advanced modeling of the biophysics, pharmacokinetics, and pharmacodynamics of ATAC mediated endocytosis and degradation. The ATAC platform enables the modular design and synthesis of ATACs extendable across the extracellular proteome to a wide range of proteins involved in the pathogenesis of human diseases. Avilar is leveraging the ATAC platform to create a broad and diverse pipeline of first-in-class extracellular protein degraders. Avilar was founded and financed by RA Capital Management and based in Waltham, MA. For more information, please visit and follow us on Twitter @Avilar_Tx and on LinkedIn.

Media Contact:
Kathryn Morris
The Yates Network

❮ Back to Press Releases